https://www.selleckchem.com/pr....oducts/5-ethynyl-2--
7%). The incidence of TRAEs was significantly higher in elderly patients (≥ 65 vs 65years; ≥ 75 vs 75years); patients with lower C-reactive protein levels ( 5 vs ≥ 5mg/dL); and patients with vs without a past medical history, including hepatic, thyroid, and autoimmune diseases. The 6- and 12-month survival rates were 71.8% and 57.9%, respectively. The safety profile of nivolumab monotherapy in Japanese patients with advanced RCC was similar to that in the phase 3 CheckMate 025 trial. No new safety signals
Curtir
Comentario
Compartilhar
